Company: NCEL
Filing Date: 2025-02-10
Form Type: 425
Source: 0001213900-25-011502
Chunk: 1

Company: NewcelX Ltd.
Filing Date: 2025-02-10
Form: 425
Chunk 1
---

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies

| ● | Revolutionizing Diabetes Treatment: Introduction                       
 of cutting-edge, multi-targeted innovation to transform diabetes care. |

| ● | Diabetes more than just a Metabolic Disorder:                                                                              
 Diabetes is a multi-systemic disease impacting the central nervous system (CNS), immune function, and cellular metabolism. |

| ● | Powerful Merger Synergies: Uniting the                                                                                
 core competencies of both organizations in order to create a holistic solution for comprehensive diabetes management. |

ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL
— February 10, 2025, NLS Pharmaceutics Ltd. (“NLS”) (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company
focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kadimastem
Ltd. (“Kadimastem”) (TASE: KDST.TA), a clinical-stage cell therapy company developing and manufacturing “off-the-shelf”
allogeneic cell products for the treatment of neurodegenerative diseases and potential cure for diabetes, are on a mission to create a
leading biotechnology entity. The upcoming expected merger aims to transform the treatment landscape for complex conditions such as diabetes.
By uniting the core competencies of both organizations, NLS and Kadimastem believe that this merger is positioned to potentially create
a holistic solution that addresses the multifaceted challenges of diabetes management.

While GLP-1 receptor agonists have brought
significant progress in diabetes care, they do not fully address the systemic and neurological complications of the disease. Their
focus on glucose control and weight loss overlooks key factors such as neuroinflammation, circadian rhythm disruptions,
and metabolic resilience. Furthermore, tolerance issues, gastrointestinal side effects, and long-term safety concerns underscore
the need for alternative and complementary therapeutic strategies. Diabetes is more than a metabolic disorder—it is a multi-systemic
disease affecting the central nervous system (CNS), immune function, and cellular metabolism. A growing body of research highlights
the connection between diabetes, neurodegeneration, and sleep disorders, collectively known as Diabetes-Associated Neurological
and Sleep Disorders (DANS). Addressing these complex interactions requires a paradigm shift toward multi-target therapeutic strategies.

Introducing DOXA: A Multi-